{"organizations": [], "uuid": "18174cb571944c0049eedd9972cd528e8286c8ab", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-adaptimmune-therapeutics-says-on-j/brief-adaptimmune-therapeutics-says-on-jan-5-co-entered-into-agreement-with-cell-gene-therapy-catapult-for-vector-production-in-uk-idUSFWN1P30PX", "country": "US", "domain_rank": 408, "title": "BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.701, "site_type": "news", "published": "2018-01-08T21:22:00.000+02:00", "replies_count": 0, "uuid": "18174cb571944c0049eedd9972cd528e8286c8ab"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-adaptimmune-therapeutics-says-on-j/brief-adaptimmune-therapeutics-says-on-jan-5-co-entered-into-agreement-with-cell-gene-therapy-catapult-for-vector-production-in-uk-idUSFWN1P30PX", "ord_in_thread": 0, "title": "BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK", "locations": [], "entities": {"persons": [], "locations": [{"name": "uk", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "adaptimmune therapeutics plc", "sentiment": "none"}, {"name": "spear", "sentiment": "none"}, {"name": "vector", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Adaptimmune Therapeutics Plc:\n* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING\n* ADAPTIMMUNE THERAPEUTICS - AGREEMENT IS FOR TERM OF 5 YEARS WITH EARLIER TERMINATION AVAILABLE TO BOTH PARTIES ON PROVISION OF 12 MONTHSâ€™ NOTICE\n* ADAPTIMMUNE THERAPEUTICS PLC - AGREEMENT WILL ENABLE CO TO HAVE ITS OWN DEDICATED VECTOR MANUFACTURING SPACE IN UK\n* ADAPTIMMUNE - AGREEMENT TO ENSURE VECTOR SUPPLY PRODUCTION BEYOND 2020 FOR ONGOING STUDIES WITH 3 SPEAR T-CELL THERAPIES, MAGE-A4, MAGE-A10 AND AFP Source text ( bit.ly/2m7wkSH ) Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2m7wkSH"], "published": "2018-01-08T21:22:00.000+02:00", "crawled": "2018-01-09T17:19:27.029+02:00", "highlightTitle": ""}